Cost-Effectiveness of Pembrolizumab With or Without Chemotherapy for Stage IV Non-Squamous NSCLC with High PD-L1 in Switzerland

被引：0
|
作者：
Pardo, E. [1 ]
Barbier, M. [2 ]
Panje, C. [3 ]
Gautschi, O. [4 ]
Lupatsch, J. [5 ]
机构：
[1] Canton Hosp Lucerne, Med Oncol, Internal Med, Luzern, Switzerland
[2] Univ Basel, Inst Pharmaceut Med Ecpm, Basel, Switzerland
[3] Cantonal Hosp St Gallen, Radiat Oncol, St Gallen, Switzerland
[4] Canton Hosp Lucerne, Luzern, Switzerland
[5] Univ Basel, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
cost-effectiveness; Pembrolizumab; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P08.03
引用
收藏
页码：S992 / S992
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
    Zheng, Zhiwei
    Lin, Jingrong
    Zhu, Huide
    Cai, Hongfu
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [22] A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Aebi, Stefan
    Dedes, Konstantin
    Diebold, Joachim
    Pietrini, Mario
    Klingbiel, Dirk
    von Moos, Roger
    Gautschi, Oliver
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : 1846 - 1855
  • [23] Pembrolizumab with High PD-L1: Who Are Non-Responders?
    Shigematsu, F.
    Kogure, Y.
    Torii, A.
    Yamada, A.
    Ishida, A.
    Niwa, H.
    Nakahata, M.
    Oka, S.
    Kitagawa, C.
    Oki, M.
    Saka, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S974 - S974
  • [24] Cost-Effectiveness of PD-L1 Testing for Guiding Immunotherapy in Non-Small Cell Lung Cancer (Stage IIA-IIIB & Stage IV) Patients in China
    Li, Y.
    Chen, Y.
    Ming, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S721 - S721
  • [25] Impact of proton pump inhibitor on ICI with or without chemotherapy for NSCLC with high PD-L1 TPS
    Sawada, Ryo
    Kawachi, Hayato
    Yamada, Tadaaki
    Tamiya, Motohiro
    Negi, Yoshiki
    Goto, Yasuhiro
    Nakao, Akira
    Shiotsu, Shinsuke
    Takeda, Takayuki
    Okada, Asuka
    Harada, Taishi
    Date, Koji
    Chihara, Yusuke
    Hasegawa, Isao
    Kijima, Takashi
    Takayama, Koichi
    CANCER RESEARCH, 2024, 84 (06)
  • [26] Cost-effectiveness analysis of pembrolizumab for patients with advanced esophageal cancer at PD-L1 combined positive score ≥10
    Xie, Qian
    Luo, Yaxin
    Peng, Xingchen
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (15) : 1095 - 1103
  • [27] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB MONOTHERAPY IN ADVANCED PD-L1 ≥50% NON-SMALL CELL LUNG CANCER (NSCLC) IN THE IRISH SETTING
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S61 - S61
  • [28] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1
    Radhakrishnan, V.
    Banavali, S.
    Gupta, S.
    Kumar, A.
    Deshmukh, C. D.
    Nag, S.
    Beniwal, S. K.
    Gopichand, M.
    Naik, R.
    Lakshmaiah, K. C.
    Mandavia, D.
    Ramchandra, M.
    Prabhash, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis
    Wu, Bin
    Lu, Shun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (05) : 1770 - +
12345